Vitamin B12 Bioconjugates in Pharmaceutical Design
Başlık:
Vitamin B12 Bioconjugates in Pharmaceutical Design
Yazar:
Workinger, Jayme L., author.
ISBN:
9780438029149
Yazar Ek Girişi:
Fiziksel Tanımlama:
1 electronic resource (288 pages)
Genel Not:
Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.
Advisors: Robert P. Doyle Committee members: Mark Braiman; Joseph Chaiken; John Franck; Ivan Korendovych; Beth Prieve.
Özet:
This thesis addresses several questions focused on the vitamin B12 (B12) dietary uptake pathway, in particular that of the enteric B12 transport protein intrinsic factor (IF) and its receptor cubilin, and the expression and exploitation of IF/cubilin in pharmaceutical development.
Q1: (Chapter 2) Does an 89Zr-B12 conjugate allow for improved background/noise ratio, relative to 99mTc and 64Cu B12 conjugates, in in vivo tumor uptake?
Goal: Conduct positron emission tomography (PET) imaging and biodistribution studies in mice bearing MDA-MB-453 breast cancer tumors using a new 89Zr-B12 conjugate.
Q2: (Chapter 3) What is the uptake of systemically administered holo-intrinisic factor bound to 89Zr-B12 in vivo?
Goal: Conduct PET imaging and biodistribution studies in healthy mouse models using IF-89Zr-B12 and assign organ distribution to target receptors.
Q3: (Chapter 4) Are functional cubilin and megalin receptors expressed in human fetal small intestinal cells?
Goal: Design a fluorescent assay to establish functional cubilin and megalin expression and conduct western blotting to complement observations.
Q4: (Chapter 4) Does B12-Exendin-4, a conjugate of B12 and the diabetes drug exendin-4 (Ex-4; a peptide agonist of the glucagon like peptide receptor 1) show reduced central nervous system (CNS) penetrance, thus reducing the common side effect of nausea that is observed in patients taking Ex-4?
Goal: Systemically administer fluorescently labeled Ex-4, B12, and B12-Ex4 and observe CNS uptake in rats through immunohistochemistry and confocal microscopy.
Q5: (Chapter 5) Does systemically administered holo-IF prevent aminoglycoside antibiotic induced hearing loss in guinea pigs?
Goal: Induce hearing loss in guinea pigs with the aminoglycoside kanamycin and prevent such loss with co-administration of holo-IF.
Notlar:
School code: 0659
Tüzel Kişi Ek Girişi:
Mevcut:*
Yer Numarası | Demirbaş Numarası | Shelf Location | Lokasyon / Statüsü / İade Tarihi |
---|---|---|---|
XX(678123.1) | 678123-1001 | Proquest E-Tez Koleksiyonu | Arıyor... |
On Order
Liste seç
Bunu varsayılan liste yap.
Öğeler başarıyla eklendi
Öğeler eklenirken hata oldu. Lütfen tekrar deneyiniz.
:
Select An Item
Data usage warning: You will receive one text message for each title you selected.
Standard text messaging rates apply.